Clinical Trials Logo

Filter by:
  • Not yet recruiting  
  • Page [1]
NCT ID: NCT06441006 Not yet recruiting - Clinical trials for Tuberculosis, Pulmonary

Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis

PRISM-TB
Start date: November 1, 2024
Phase: Phase 3
Study type: Interventional

PRISM-TB is an international, multicenter, open-label, randomized, controlled, pragmatic, stratified medicine, treatment shortening, noninferiority Phase 3 clinical trial for fluoroquinolone-susceptible multidrug-resistant/rifampin-resistant pulmonary tuberculosis (FQ-S MDR/RR-TB). The trial objective is to evaluate whether stratified medicine treatment strategies for FQ-S MDR/RR-TB, defined by a pre-specified risk stratification algorithm, have noninferior efficacy to a one-size-fits-all control regimen (the local standard-of-care [SOC] regimen consistent with preferred regimen(s) in international guidelines), as measured by TB-related unfavorable outcomes at Week 73.

NCT ID: NCT06132542 Not yet recruiting - Clinical trials for Premature Ovarian Failure

Autologous ADMSC Transplantation in Patients With POI

ADMSC
Start date: January 15, 2024
Phase: Phase 1
Study type: Interventional

The primary ovarian insufficiency (premature ovarian failure, premature ovarian insufficiency, premature menopause) is a hypergonadotropic hypogonadism, that failure of the ovarian function in woman younger than 40 years. Fat derived stem cells are mainly mesenchymal stem cells and found to be effective treatment in joint and bone regeneration. We are planning to investigate the effectiveness of adipose stem cell on ovarian tissue regeneration for patients with premature ovarian failure.

NCT ID: NCT04377243 Not yet recruiting - Clinical trials for Renal Failure Chronic

Immunotherapy of Chronic Kidney Failure

Start date: June 16, 2020
Phase: Phase 2
Study type: Interventional

Kidney failure can result from inflammatory renal disease in the context of autoimmunity because the kidney is targeted by host's immune response against self. There are many causes to this, but abnormal kidney function tests, i.e., BUN and creatinine, can reveal the disease. Oral delivery of kidney cells is ought to produce the immune tolerance - phenomenon is known as oral tolerance. Preliminary studies produced convincing evidence that this hypothesis holds true and has not produced any adverse side effects. Intended open label Phase II aims to confirm these findings.